Get started
Aquestive Therapeutics, Inc.Aquestive Therapeutics, Inc.Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsETFs

AQST chart


Full chart

AQST upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪636.32 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.69 USD
Net income (FY)
‪−44.14 M‬ USD
Revenue (FY)
‪57.56 M‬ USD
Shares float
‪111.23 M‬
Beta (1Y)
1.00

Employees


Employees (FY)
142
Change (1Y)
+7 +5.19%
Revenue / Employee (1Y)
‪405.36 K‬ USD
Net income / Employee (1Y)
‪−310.82 K‬ USD

About Aquestive Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Daniel Barber
Website
aquestive.com
Headquarters
Warren
Founded
2004
ISIN
US03843E1047
FIGI
BBG00L9HP0Z0
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Check out other big names from the same industry as AQST.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AQST news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AQST is 5.90 USD — it has increased by 12.15% in the past 24 hours. Watch Aquestive Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aquestive Therapeutics, Inc. stocks are traded under the ticker AQST.
AQST stock has risen by 6.29% compared to the previous week, the month change is a 51.65% rise, over the last year Aquestive Therapeutics, Inc. has showed a 18.85% increase.
We've gathered analysts' opinions on Aquestive Therapeutics, Inc. future price: according to them, AQST price has a max estimate of 15.00 USD and a min estimate of 4.75 USD. Watch AQST chart and read a more detailed Aquestive Therapeutics, Inc. stock forecast: see what analysts think of Aquestive Therapeutics, Inc. and suggest that you do with its stocks.
AQST reached its all-time high on Sep 13, 2018 with the price of 20.70 USD, and its all-time low was 0.62 USD and was reached on Jul 1, 2022. View more price dynamics on AQST chart.
See other stocks reaching their highest and lowest prices.
AQST stock is 20.12% volatile and has beta coefficient of 1.00. Track Aquestive Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aquestive Therapeutics, Inc. there?
Today Aquestive Therapeutics, Inc. has the market capitalization of ‪636.32 M‬, it has decreased by −2.42% over the last week.
Yes, you can track Aquestive Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Aquestive Therapeutics, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
AQST earnings for the last quarter are −0.14 USD per share, whereas the estimation was −0.17 USD resulting in a 16.00% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about Aquestive Therapeutics, Inc. earnings.
Aquestive Therapeutics, Inc. revenue for the last quarter amounts to ‪10.00 M‬ USD, despite the estimated figure of ‪11.32 M‬ USD. In the next quarter, revenue is expected to reach ‪12.97 M‬ USD.
AQST net income for the last quarter is ‪−13.55 M‬ USD, while the quarter before that showed ‪−22.93 M‬ USD of net income which accounts for 40.92% change. Track more Aquestive Therapeutics, Inc. financial stats to get the full picture.
No, AQST doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 26, 2025, the company has 142 employees. See our rating of the largest employees — is Aquestive Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aquestive Therapeutics, Inc. EBITDA is ‪−52.02 M‬ USD, and current EBITDA margin is −52.21%. See more stats in Aquestive Therapeutics, Inc. financial statements.
Like other stocks, AQST shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aquestive Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aquestive Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aquestive Therapeutics, Inc. stock shows the strong buy signal. See more of Aquestive Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.